Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma

EuroLVD and DRAGON Trials Collaborative; Jens Smits; Steven Chau; Sinéad James; Remon Korenblik; Madita Tschögl; Pieter Arntz; Jan Bednarsch; Luis Abreu de Carvalho; Olivier Detry; Joris Erdmann; Thomas Gruenberger; Laurens Hermie; Ulf Neumann; Per Sandström; Robert Sutcliffe; Alban Denys; Emmanuel Melloul; Maxime Dewulf; Christiaan van der Leij; Ronald M van Dam

doi:10.1016/j.hpb.2024.07.407

Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma

EuroLVD and DRAGON Trials Collaborative, Jens Smits, Steven Chau, Sinéad James, Remon Korenblik, Madita Tschögl, Pieter Arntz, Jan Bednarsch, Luis Abreu de Carvalho, Olivier Detry, Joris Erdmann, Thomas Gruenberger, Laurens Hermie, Ulf Neumann, Per Sandström, Robert Sutcliffe, Alban Denys, Emmanuel Melloul, Maxime Dewulf^*, Christiaan van der LeijRonald M van Dam^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

2 Downloads (Pure)

Abstract

BACKGROUND: Major hepatectomy in perihilar cholangiocarcinoma (pCCA) patients with a small future liver remnant (FLR) risks posthepatectomy liver failure (PHLF). This study examines combined portal and hepatic vein embolisation (PVE/HVE) to increase preoperative FLR volume and potentially decrease PHLF rates.

METHODS: In this retrospective, multicentre, observational study, data was collected from centres affiliated with the DRAGON Trials Collaborative and the EuroLVD registry. The study included pCCA patients who underwent PVE/HVE between July 2016 and January 2023.

RESULTS: Following PVE/HVE, 28% of patients (9/32) experienced complications, with 22% (7/32) necessitating biliary interventions for cholangitis. The median degree of hypertrophy after a median of 16 days was 16% with a kinetic growth rate of 6.8% per week. 69% of patients (22/32) ultimately underwent surgical resection. Cholangitis after PVE/HVE was associated with unresectability. After resection, 55% of patients (12/22) experienced complications, of which 23% (5/22) were Clavien-Dindo grade III or higher. The 90-day mortality after resection was 0%.

CONCLUSION: PVE/HVE quickly enhances the kinetic growth rate in pCCA patients. Cholangitis impairs chances on resection significantly. Resection after PVE/HVE is associated with low levels of 90-day mortality. The study highlights the potential of PVE/HVE in improving safety and outcomes in pCCA undergoing resection.

Original language	English
Pages (from-to)	1458-1466
Number of pages	9
Journal	HPB
Volume	26
Issue number	12
Early online date	16-Jul-2024
DOIs	https://doi.org/10.1016/j.hpb.2024.07.407
Publication status	Published - Dec-2024

Access to Document

10.1016/j.hpb.2024.07.407Licence: CC BY

Combined portal and hepatic vein embolisation in perihilar cholangiocarcinomaFinal publisher's version, 294 KBLicence: CC BY

Handle.net

Persistent link

Cite this

EuroLVD and DRAGON Trials Collaborative, Smits, J., Chau, S., James, S., Korenblik, R., Tschögl, M., Arntz, P., Bednarsch, J., Abreu de Carvalho, L., Detry, O., Erdmann, J., Gruenberger, T., Hermie, L., Neumann, U., Sandström, P., Sutcliffe, R., Denys, A., Melloul, E., Dewulf, M., ... van Dam, R. M. (2024). Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma. HPB, 26(12), 1458-1466. https://doi.org/10.1016/j.hpb.2024.07.407

@article{a4af07fe00104bf6a3c86cd137fecc29,

title = "Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma",

abstract = "BACKGROUND: Major hepatectomy in perihilar cholangiocarcinoma (pCCA) patients with a small future liver remnant (FLR) risks posthepatectomy liver failure (PHLF). This study examines combined portal and hepatic vein embolisation (PVE/HVE) to increase preoperative FLR volume and potentially decrease PHLF rates.METHODS: In this retrospective, multicentre, observational study, data was collected from centres affiliated with the DRAGON Trials Collaborative and the EuroLVD registry. The study included pCCA patients who underwent PVE/HVE between July 2016 and January 2023.RESULTS: Following PVE/HVE, 28% of patients (9/32) experienced complications, with 22% (7/32) necessitating biliary interventions for cholangitis. The median degree of hypertrophy after a median of 16 days was 16% with a kinetic growth rate of 6.8% per week. 69% of patients (22/32) ultimately underwent surgical resection. Cholangitis after PVE/HVE was associated with unresectability. After resection, 55% of patients (12/22) experienced complications, of which 23% (5/22) were Clavien-Dindo grade III or higher. The 90-day mortality after resection was 0%.CONCLUSION: PVE/HVE quickly enhances the kinetic growth rate in pCCA patients. Cholangitis impairs chances on resection significantly. Resection after PVE/HVE is associated with low levels of 90-day mortality. The study highlights the potential of PVE/HVE in improving safety and outcomes in pCCA undergoing resection.",

author = "{EuroLVD and DRAGON Trials Collaborative} and Jens Smits and Steven Chau and Sin{\'e}ad James and Remon Korenblik and Madita Tsch{\"o}gl and Pieter Arntz and Jan Bednarsch and {Abreu de Carvalho}, Luis and Olivier Detry and Joris Erdmann and Thomas Gruenberger and Laurens Hermie and Ulf Neumann and Per Sandstr{\"o}m and Robert Sutcliffe and Alban Denys and Emmanuel Melloul and Maxime Dewulf and {van der Leij}, Christiaan and {van Dam}, {Ronald M} and {de Boer}, {Marieke T.} and Bokkers, {Reinoud P.H.}",

year = "2024",

month = dec,

doi = "10.1016/j.hpb.2024.07.407",

language = "English",

volume = "26",

pages = "1458--1466",

journal = "HPB",

issn = "1365-182X",

publisher = "ELSEVIER SCI LTD",

number = "12",

}

EuroLVD and DRAGON Trials Collaborative, Smits, J, Chau, S, James, S, Korenblik, R, Tschögl, M, Arntz, P, Bednarsch, J, Abreu de Carvalho, L, Detry, O, Erdmann, J, Gruenberger, T, Hermie, L, Neumann, U, Sandström, P, Sutcliffe, R, Denys, A, Melloul, E, Dewulf, M, van der Leij, C & van Dam, RM 2024, 'Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma', HPB, vol. 26, no. 12, pp. 1458-1466. https://doi.org/10.1016/j.hpb.2024.07.407

TY - JOUR

T1 - Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma

AU - EuroLVD and DRAGON Trials Collaborative

AU - Smits, Jens

AU - Chau, Steven

AU - James, Sinéad

AU - Korenblik, Remon

AU - Tschögl, Madita

AU - Arntz, Pieter

AU - Bednarsch, Jan

AU - Abreu de Carvalho, Luis

AU - Detry, Olivier

AU - Erdmann, Joris

AU - Gruenberger, Thomas

AU - Hermie, Laurens

AU - Neumann, Ulf

AU - Sandström, Per

AU - Sutcliffe, Robert

AU - Denys, Alban

AU - Melloul, Emmanuel

AU - Dewulf, Maxime

AU - van der Leij, Christiaan

AU - van Dam, Ronald M

AU - de Boer, Marieke T.

AU - Bokkers, Reinoud P.H.

PY - 2024/12

Y1 - 2024/12

N2 - BACKGROUND: Major hepatectomy in perihilar cholangiocarcinoma (pCCA) patients with a small future liver remnant (FLR) risks posthepatectomy liver failure (PHLF). This study examines combined portal and hepatic vein embolisation (PVE/HVE) to increase preoperative FLR volume and potentially decrease PHLF rates.METHODS: In this retrospective, multicentre, observational study, data was collected from centres affiliated with the DRAGON Trials Collaborative and the EuroLVD registry. The study included pCCA patients who underwent PVE/HVE between July 2016 and January 2023.RESULTS: Following PVE/HVE, 28% of patients (9/32) experienced complications, with 22% (7/32) necessitating biliary interventions for cholangitis. The median degree of hypertrophy after a median of 16 days was 16% with a kinetic growth rate of 6.8% per week. 69% of patients (22/32) ultimately underwent surgical resection. Cholangitis after PVE/HVE was associated with unresectability. After resection, 55% of patients (12/22) experienced complications, of which 23% (5/22) were Clavien-Dindo grade III or higher. The 90-day mortality after resection was 0%.CONCLUSION: PVE/HVE quickly enhances the kinetic growth rate in pCCA patients. Cholangitis impairs chances on resection significantly. Resection after PVE/HVE is associated with low levels of 90-day mortality. The study highlights the potential of PVE/HVE in improving safety and outcomes in pCCA undergoing resection.

AB - BACKGROUND: Major hepatectomy in perihilar cholangiocarcinoma (pCCA) patients with a small future liver remnant (FLR) risks posthepatectomy liver failure (PHLF). This study examines combined portal and hepatic vein embolisation (PVE/HVE) to increase preoperative FLR volume and potentially decrease PHLF rates.METHODS: In this retrospective, multicentre, observational study, data was collected from centres affiliated with the DRAGON Trials Collaborative and the EuroLVD registry. The study included pCCA patients who underwent PVE/HVE between July 2016 and January 2023.RESULTS: Following PVE/HVE, 28% of patients (9/32) experienced complications, with 22% (7/32) necessitating biliary interventions for cholangitis. The median degree of hypertrophy after a median of 16 days was 16% with a kinetic growth rate of 6.8% per week. 69% of patients (22/32) ultimately underwent surgical resection. Cholangitis after PVE/HVE was associated with unresectability. After resection, 55% of patients (12/22) experienced complications, of which 23% (5/22) were Clavien-Dindo grade III or higher. The 90-day mortality after resection was 0%.CONCLUSION: PVE/HVE quickly enhances the kinetic growth rate in pCCA patients. Cholangitis impairs chances on resection significantly. Resection after PVE/HVE is associated with low levels of 90-day mortality. The study highlights the potential of PVE/HVE in improving safety and outcomes in pCCA undergoing resection.

U2 - 10.1016/j.hpb.2024.07.407

DO - 10.1016/j.hpb.2024.07.407

M3 - Article

C2 - 39277435

SN - 1365-182X

VL - 26

SP - 1458

EP - 1466

JO - HPB

JF - HPB

IS - 12

ER -

Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma

Abstract

Access to Document

Handle.net

Fingerprint

Cite this